Details for New Drug Application (NDA): 214511
The generic ingredient in LUMISIGHT is pegulicianine acetate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pegulicianine acetate profile page.
Summary for 214511
| Tradename: | LUMISIGHT |
| Applicant: | Lumicell |
| Ingredient: | pegulicianine acetate |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 214511
Generic Entry Date for 214511*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 214511
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511 | NDA | Lumicell, Inc. | 82292-040 | 82292-040-10 | 10 VIAL in 1 CARTON (82292-040-10) / 3.9 mL in 1 VIAL (82292-040-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 39MG BASE/VIAL | ||||
| Approval Date: | Apr 17, 2024 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 17, 2029 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 8, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Sep 1, 2030 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Complete Access Available with Subscription
